Thu, 11/12/2009 - 12:49
Interview: Pharma MNCs must be proactive in IP protection in China - Jones Day partner
by Karl Zhong
Intellectual property protection has been and will likely continue to be an area of concern for multinational corporations operating in China. Interfax recently spoke with Benjamin Bai from the international law firm Jones Day, a recognized expert on Chinese IP issues, on the current IP environment in China and his take on the optimal IP strategy for MNCs.
"Pharmaceutical multinational corporations should seek patent protection for their products in China the moment they enter the market and not wait until their products are doing well in the market years later" - Benjamin Bai, Jones Day partner.
Shanghai. November 12. INTERFAX-CHINA - Multinational pharmaceutical corporations need to have a proactive intellectual property (IP) strategy in China as they expand business and research and development (R & D) efforts, according to Benjamin Bai, a partner at international law firm Jones Day.
